HIF1A and Patent ductus arteriosus: Another HIF-1α inhibitor used in vivo, TX-2098, led to a lower expression of the vascular endothelial growth factor (VEGF), which is involved in tumor growth and metastasis, and a reduced expression of glycolytic enzymes, including ALDOA, resulting in a prolonged survival on a xenograft model of PDA [37].